ABSTRACT:
The landscape of diabetes management is undergoing a significant transformation driven by advancements in Novel Drug Delivery Systems (NDDS) that prioritize patient adherence and physiological precision. While traditional subcutaneous injections remain the gold standard, they are increasingly being replaced by smart, minimally invasive technologies designed to mimic the endocrine pancreas. In 2026, the focus has shifted toward Smart Insulin Patches—glucose-responsive systems that release insulin only when needed—and Oral Insulin Nano-formulations that overcome the gastrointestinal barrier using lipid-based carriers. Additionally, the miniaturization of Automated Insulin Delivery (AID) systems, such as the ultra-compact Tandem Mobi, and the development of Long-acting GLP-1/GIP co-agonist implants are reducing the daily burden of self-care. This abstract evaluates how these delivery innovations, ranging from biodegradable microneedles to hydrogel-based depots, are overcoming the pharmacokinetic limitations of conventional therapy to provide more stable glycemic profiles and improve the overall quality of life for patients with both Type 1 and Type 2 diabetes.